Teachers Advisors LLC Raises Holdings in Neurocrine Biosciences, Inc. (NBIX)

Teachers Advisors LLC grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 10.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 91,550 shares of the company’s stock after acquiring an additional 8,903 shares during the period. Teachers Advisors LLC owned 0.10% of Neurocrine Biosciences worth $4,211,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Teacher Retirement System of Texas lifted its position in Neurocrine Biosciences by 0.8% during the second quarter. Teacher Retirement System of Texas now owns 6,966 shares of the company’s stock worth $320,000 after acquiring an additional 57 shares during the last quarter. Utah Retirement Systems lifted its position in Neurocrine Biosciences by 1.9% during the second quarter. Utah Retirement Systems now owns 16,000 shares of the company’s stock worth $736,000 after acquiring an additional 300 shares during the last quarter. Schroder Investment Management Group lifted its position in Neurocrine Biosciences by 1.7% during the first quarter. Schroder Investment Management Group now owns 20,496 shares of the company’s stock worth $856,000 after acquiring an additional 335 shares during the last quarter. Nuveen Asset Management LLC lifted its position in Neurocrine Biosciences by 5.6% during the first quarter. Nuveen Asset Management LLC now owns 14,464 shares of the company’s stock worth $626,000 after acquiring an additional 763 shares during the last quarter. Finally, Aperio Group LLC lifted its position in Neurocrine Biosciences by 3.7% during the second quarter. Aperio Group LLC now owns 22,324 shares of the company’s stock worth $1,027,000 after acquiring an additional 789 shares during the last quarter.

Several equities research analysts have issued reports on the stock. Cowen and Company restated an “outperform” rating and set a $65.00 price objective (up from $60.00) on shares of Neurocrine Biosciences in a research report on Wednesday, August 9th. BidaskClub upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Leerink Swann restated an “outperform” rating and set a $72.00 price objective (up from $67.00) on shares of Neurocrine Biosciences in a research report on Tuesday. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $70.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, July 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $58.00 price objective on shares of Neurocrine Biosciences in a research report on Sunday, September 17th. Two research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Neurocrine Biosciences has a consensus rating of “Buy” and an average price target of $68.81.

In other Neurocrine Biosciences news, insider Christopher Flint Obrien sold 6,925 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $61.04, for a total value of $422,702.00. Following the sale, the insider now directly owns 55,898 shares in the company, valued at approximately $3,412,013.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Haig P. Bozigian sold 22,500 shares of the stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $50.00, for a total transaction of $1,125,000.00. Following the completion of the sale, the insider now owns 154,601 shares in the company, valued at $7,730,050. The disclosure for this sale can be found here. Insiders sold a total of 132,580 shares of company stock worth $7,440,850 over the last quarter. Corporate insiders own 4.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://ledgergazette.com/2017/10/14/teachers-advisors-llc-raises-holdings-in-neurocrine-biosciences-inc-nbix.html.

Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at 62.15 on Friday. Neurocrine Biosciences, Inc. has a 52 week low of $37.35 and a 52 week high of $63.77. The company has a 50-day moving average of $58.56 and a 200-day moving average of $51.23. The company’s market capitalization is $5.48 billion.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.01). The business had revenue of $6.34 million for the quarter, compared to analyst estimates of $0.61 million. During the same quarter in the previous year, the company earned ($0.46) EPS. On average, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post ($2.45) EPS for the current year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and dev

A number of other hedge funds also recently modified their holdings of the business. Teacher Retirement System of Texas lifted its position in Neurocrine Biosciences by 0.8% during the second quarter. Teacher Retirement System of Texas now owns 6,966 shares of the company’s stock worth $320,000 after acquiring an additional 57 shares during the last quarter. Utah Retirement Systems lifted its position in Neurocrine Biosciences by 1.9% during the second quarter. Utah Retirement Systems now owns 16,000 shares of the company’s stock worth $736,000 after acquiring an additional 300 shares during the last quarter. Schroder Investment Management Group lifted its position in Neurocrine Biosciences by 1.7% during the first quarter. Schroder Investment Management Group now owns 20,496 shares of the company’s stock worth $856,000 after acquiring an additional 335 shares during the last quarter. Nuveen Asset Management LLC lifted its position in Neurocrine Biosciences by 5.6% during the first quarter. Nuveen Asset Management LLC now owns 14,464 shares of the company’s stock worth $626,000 after acquiring an additional 763 shares during the last quarter. Finally, Aperio Group LLC lifted its position in Neurocrine Biosciences by 3.7% during the second quarter. Aperio Group LLC now owns 22,324 shares of the company’s stock worth $1,027,000 after acquiring an additional 789 shares during the last quarter.

Several equities research analysts have issued reports on the stock. Cowen and Company restated an “outperform” rating and set a $65.00 price objective (up from $60.00) on shares of Neurocrine Biosciences in a research report on Wednesday, August 9th. BidaskClub upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Leerink Swann restated an “outperform” rating and set a $72.00 price objective (up from $67.00) on shares of Neurocrine Biosciences in a research report on Tuesday. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $70.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, July 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $58.00 price objective on shares of Neurocrine Biosciences in a research report on Sunday, September 17th. Two research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Neurocrine Biosciences has a consensus rating of “Buy” and an average price target of $68.81.

In other Neurocrine Biosciences news, insider Christopher Flint Obrien sold 6,925 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $61.04, for a total value of $422,702.00. Following the sale, the insider now directly owns 55,898 shares in the company, valued at approximately $3,412,013.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Haig P. Bozigian sold 22,500 shares of the stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $50.00, for a total transaction of $1,125,000.00. Following the completion of the sale, the insider now owns 154,601 shares in the company, valued at $7,730,050. The disclosure for this sale can be found here. Insiders sold a total of 132,580 shares of company stock worth $7,440,850 over the last quarter. Corporate insiders own 4.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://ledgergazette.com/2017/10/14/teachers-advisors-llc-raises-holdings-in-neurocrine-biosciences-inc-nbix.html.

Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at 62.15 on Friday. Neurocrine Biosciences, Inc. has a 52 week low of $37.35 and a 52 week high of $63.77. The company has a 50-day moving average of $58.56 and a 200-day moving average of $51.23. The company’s market capitalization is $5.48 billion.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.01). The business had revenue of $6.34 million for the quarter, compared to analyst estimates of $0.61 million. During the same quarter in the previous year, the company earned ($0.46) EPS. On average, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post ($2.45) EPS for the current year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply